ArticleObesity (Silver Spring, Md.)2022
Addressing insurance-related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery.
Article in Obesity (Silver Spring, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications.Obesity science & practice · 2026Review
- The New Obesity Treatment Landscape: Challenges and Opportunities to Promote Shared Decision-Making in People With Obesity and Type 2 Diabetes.Diabetes care · 2026Review
- Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.Diabetes, obesity & metabolism · 2026Article
- Analysis of morbid obese diabetic and non-diabetic patients: clinical and social characteristics, habits and workup to undergo bariatric surgery in Lombardy, Italy.Acta diabetologica · 2026Article
- Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.Healthcare (Basel, Switzerland) · 2026Article
- Understanding obesity treatment choices: a mixed-methods study of patient preferences and shared decision-making.Translational behavioral medicine · 2026Article
- Factors Associated with the Acceptance of Weight Loss Drugs Among Overweight and Obese Adults in Mainland China: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records.Biology methods & protocols · 2026Article
- Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.Obesity (Silver Spring, Md.) · 2025Article
- Considerations for the Use of Glucagon-like Peptide-1 Medications for Obesity in a Plastic Surgery Setting.Plastic and reconstructive surgery. Global open · 2025Article
- Socio-demographic and clinical factors associated with the receipt of anti-obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants.Diabetes, obesity & metabolism · 2025Article
- Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment.Diabetes, obesity & metabolism · 2025Article
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.JAMA health forum · 2025Article
- Obesity Medication Treatment Perspectives Among People with Overweight or Obesity.Patient preference and adherence · 2025Article
- One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.JAMA network open · 2024Article
- Weight-centric prevention of cancer.Obesity pillars · 2024Review
- Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.Diabetes, obesity & metabolism · 2024Article
- Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The past decade has witnessed significant progress in the development of new antiobesity medications, with several having greater efficacy than pharmacological agents previously approved by the Food and Drug Administration (FDA). Despite the potential of new medications to combat America's obesity crisis, access to these agents is severely limited. This Perspective presents the current coverage landscape for antiobesity medications, including the recent requirement by the US Office of Personnel Management for Federal Employees Health Benefits Program carriers to offer adequate coverage of FDA-approved antiobesity medications, and it makes parallels with conditions that made expanded insurance coverage for bariatric surgery possible, as well as emphasizes the need for additional action by the legislature and the Centers for Medicare and Medicaid Services to expand coverage of evidence-based obesity treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.